Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase III Oncology
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Adding talazoparib to enzalutamide improves outcomes in men with metastatic prostate cancer and DNA repair gene mutations.
04 Sep 2026 NCT04821622
active not recruiting Respiratory / COPD / Asthma
Is the Vaginal Microbiome and Metabolome Associated With Spontaneous Preterm Birth (sPTB) in Multiple Pregnancies?
Study investigates whether vaginal bacteria in twin pregnancies are linked to early delivery to identify potential prevention treatments.
04 Sep 2026 NCT06053697
active not recruiting Phase III
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Adding tafasitamab to standard lymphoma treatment improves outcomes in patients with relapsed or refractory follicular or marginal zone lymphoma.
04 Sep 2026 NCT04680052
● Recruiting Phase III
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Depemokimab added to standard care reduced flares in adults with uncontrolled hypereosinophilic syndrome over 52 weeks.
04 Sep 2026 NCT05334368
● Recruiting Phase III
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Study comparing NXT007 with emicizumab for preventing bleeding in hemophilia A patients aged 12 and over.
04 Sep 2026 NCT07416604
● Recruiting
Post-Market Clinical Follow-up (PMCF) Study of the Pitch-Patch for the Augmentation or Reinforcement of the Rotator Cuff
Study tracking long-term safety and effectiveness of Pitch-Patch, a synthetic reinforcement patch for rotator cuff tear repair, in 37 patients.
04 Sep 2026 NCT05906004
● Recruiting Cardiology / Cardiovascular
Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
What is being tested: The Edwards EVOQUE system is undergoing real-world safety and clinical efficacy evaluation across multiple European centres in a prospective, single-arm…
04 Sep 2026 NCT06569602
● Recruiting Phase III Oncology
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
What is being tested: This phase 3 trial evaluates whether lower doses of Androgen Receptor Pathway Inhibitors (ARPIs) can achieve equivalent clinical effectiveness compared…
04 Sep 2026 NCT07751133
● Recruiting Phase I Oncology
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
ORIC-114 is being tested as a novel therapeutic agent either alone or combined with chemotherapy in patients with advanced solid tumors carrying EGFR or…
04 Sep 2026 NCT05315700
active not recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Adding immunotherapy to standard HER2 treatment reduces breast cancer recurrence risk in patients with residual disease after pre-surgery therapy.
03 Sep 2026 NCT04873362
active not recruiting Phase III Oncology
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Trial testing combination immunotherapy plus targeted drugs for untreated advanced melanoma with BRAF mutations.
03 Sep 2026 NCT04657991
active not recruiting Phase II Oncology
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Trial comparing two immunotherapy combinations with chemotherapy for advanced head and neck cancer, regardless of PD-L1 status.
03 Sep 2026 NCT06727565
● Recruiting Phase II Oncology
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
What is being tested: Irinotecan-ChemoSeed, a locally-delivered chemotherapy implant, is being evaluated for safety, tolerability, and maximum tolerated dose (MTD) in patients undergoing surgical…
03 Sep 2026 NCT07356973
active not recruiting Phase I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington’s Disease
RG6496 is being tested in Huntington's disease gene carriers to assess its safety, tolerability, and how the body processes it.
02 Sep 2026 NCT07246941
active not recruiting
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
Study tracking heart disease progression in children with MYBPC3 gene mutations to understand symptoms, treatments, and quality of life.
02 Sep 2026 NCT05112237
● Recruiting Phase III
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
A trial testing a new drug called atumelnant in adults with a genetic condition affecting the adrenal glands to check if it works, is…
02 Sep 2026 NCT07144163
active not recruiting Phase III Oncology
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Adding quemliclustat to standard chemotherapy did not improve survival in advanced pancreatic cancer compared to chemotherapy alone.
02 Sep 2026 NCT06608927
active not recruiting Phase III
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Trial comparing subcutaneous versus intravenous isatuximab combined with pomalidomide and dexamethasone in relapsed multiple myeloma.
02 Sep 2026 NCT05405166
● Recruiting Gastroenterology
Vision Baby : The Measurement of Vital Signs in Neonates by Lifelight® Software in Comparison to the Standard of Care
Vision Baby Study Summary Lifelight® software uses facial video to measure vital signs in newborns, compared against standard monitoring equipment.
02 Sep 2026 NCT07799870
● Recruiting Phase III Oncology
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
What is being tested: BNT324, a novel therapeutic agent, is being evaluated against docetaxel (standard chemotherapy) combined with corticosteroids in patients with metastatic castration-resistant…
02 Sep 2026 NCT07365995
● Recruiting Phase III Cardiology / Cardiovascular
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
What is being tested: IKT-001, a novel therapeutic agent, is being evaluated for efficacy and safety in treating WHO Group 1 pulmonary arterial hypertension…
02 Sep 2026 NCT07365332
● Recruiting Phase IV Respiratory / COPD / Asthma
A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy
What is being tested: The ENCOMPASS study compares diagnostic accuracy and safety outcomes between CT-guided percutaneous lung biopsy and shape-sensing robotic-assisted bronchoscopy with cone-beam…
02 Sep 2026 NCT07761351
● Recruiting Phase III Oncology
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
What is being tested: Revumenib (a menin inhibitor) combined with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukaemia (AML) harbouring NPM1…
02 Sep 2026 NCT06652438
● Recruiting
Influence of Timing of Implant Placement on Early Healing Molecular Events
Immediate dental implant placement may trigger different healing responses compared to delayed placement, based on inflammatory and bone-forming markers.
01 Sep 2026 NCT06276335
active not recruiting Phase II Oncology
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Avelumab combined with other cancer drugs was tested as maintenance therapy in advanced bladder cancer to assess safety and effectiveness.
01 Sep 2026 NCT05327530
active not recruiting Phase III Oncology
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Testing whether zanidatamab combined with chemotherapy (with or without an immunotherapy drug) works better than standard trastuzumab treatment in advanced stomach and gullet cancers.
01 Sep 2026 NCT05152147
active not recruiting Mental Health / Psychiatry
Correcting Myopia Among Secondary School Children to Increase Academic High School Attendance Rates in Rural Communities
Free glasses with teacher support increases academic high school attendance among short-sighted rural Chinese secondary school students.
01 Sep 2026 NCT04077086
● Recruiting Phase I Neurology
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson’s Disease
Drug being tested: LY3962681, a novel investigational compound undergoing evaluation for safety, tolerability, and pharmacokinetic/pharmacodynamic properties in both healthy volunteers and Parkinson's disease patients…
01 Sep 2026 NCT06565195
● Recruiting Neurology
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
What is being tested: Foslevodopa/foscarbidopa (a continuous subcutaneous infusion therapy) is being evaluated for its effects on quality of life outcomes in adults with…
01 Sep 2026 NCT07227896
● Recruiting Rare Diseases
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
What is being tested: This is a natural history study tracking disease progression in Friedreich ataxia patients over time across multiple international centers, rather…
01 Sep 2026 NCT06016946
● Recruiting Phase I Respiratory / COPD / Asthma
To Identify if a COPD Self-management App Can Safety and Appropriately Identify When Patients Are Not on the Best Medication Plan for Their COPD Symptoms and Support Their COPD Management.
What is being tested: A COPD self-management app designed to safely and accurately identify when patients are not receiving optimal inhaled therapy for their…
01 Sep 2026 NCT07797985
● Recruiting Phase III Cardiology / Cardiovascular
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
What is being tested: Once-daily oral deucrictibant extended-release tablet as a preventative treatment to reduce angioedema attack frequency in patients with hereditary angioedema (HAE),…
01 Sep 2026 NCT06679881
● Recruiting Phase III Cardiology / Cardiovascular
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
What is being tested: Zenagamtide (a novel GLP-1 receptor agonist) versus insulin glargine for glycaemic control and weight reduction in type 2 diabetes patients…
01 Sep 2026 NCT07797335
● Recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
What is being tested: Inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant in HR-positive, HER2-negative, PIK3CA-mutated breast cancer patients who have progressed after…
01 Sep 2026 NCT05646862
● Recruiting Phase III Oncology
Accelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
What is being tested: Accelerated dosing schedule of BEP chemotherapy (bleomycin, etoposide, cisplatin) compared to standard dosing in men with intermediate and poor-risk metastatic…
01 Sep 2026 NCT02582697
active not recruiting Cardiology / Cardiovascular
Point of Care NT-proBNP Testing for Suspected New Heart Failure Acute Care
Point-of-care NT-proBNP testing speeds heart failure diagnosis in acute settings, potentially improving patient outcomes and treatment times.
31 Aug 2026 NCT07793968
active not recruiting Phase II Gastroenterology
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
A trial testing whether amlitelimab injection reduces intestinal damage in adults with celiac disease unresponsive to gluten-free diet alone.
31 Aug 2026 NCT06557772
active not recruiting Phase III Oncology
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Adding apalutamide to standard hormone therapy improves progression-free survival in men with advanced prostate cancer.
31 Aug 2026 NCT02257736
active not recruiting Phase III Oncology
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Adding amivantamab to standard chemotherapy improves progression-free survival in advanced lung cancer with EGFR exon 20 mutations.
31 Aug 2026 NCT04538664
active not recruiting Phase III Diabetes / Metabolic
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
CagriSema, a new weight-loss injection, is being tested against dummy medicine and two alternatives in a 1.5-year trial, followed by observation after treatment stops.
31 Aug 2026 NCT05567796
● Recruiting Gastroenterology
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
What is being tested: Long-term safety profile and durability of therapeutic response in participants who received investigational products (IP) across iECURE parent protocols, alongside…
31 Aug 2026 NCT06805695
● Recruiting Phase I Oncology
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
What is being tested: CTIM-76, a CLDN6-directed T cell-engaging bispecific antibody, is being evaluated in a Phase 1a/1b dose escalation and expansion study to…
31 Aug 2026 NCT06515613
active not recruiting Phase II Gastroenterology
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Combining two biologic drugs (guselkumab and golimumab) tested for treating ulcerative colitis in patients who haven't responded to other treatments.
28 Aug 2026 NCT05242484
active not recruiting
Survivorship of Attune Primary Total Knee Prosthesis
Study tracking how long Attune knee replacements last in patients with osteoarthritis over 15 years.
28 Aug 2026 NCT01754363
● Recruiting Phase III Rheumatology
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
New drug icotrokinra tested against placebo for psoriatic arthritis in patients with and without previous biologic treatment.
28 Aug 2026 NCT06807424
active not recruiting Phase II Gastroenterology
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn’s Disease
Testing whether combining two existing Crohn's drugs works better than either drug alone at 48 weeks.
28 Aug 2026 NCT05242471
active not recruiting Phase III Oncology
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
New cancer drug sacituzumab tirumotecan tested against chemotherapy in previously treated endometrial cancer patients to assess survival benefits.
28 Aug 2026 NCT06132958
active not recruiting Rheumatology
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
This study compared how long patients stayed on guselkumab or IL-17 inhibitor treatments for psoriatic arthritis in routine clinical practice.
28 Aug 2026 NCT05049798
● Recruiting Oncology
Secondary Care Colorectal Cancer Pathway Review
What is being tested: A secondary care colorectal cancer pathway review examining systems and processes for detecting, diagnosing, and managing bowel cancer in hospital…
28 Aug 2026 NCT07430527
● Recruiting Oncology
Optimising Colorectal Cancer Patient Pathways
What is being tested: This trial optimises colorectal cancer patient pathways to improve early detection and survival outcomes through enhanced screening and diagnostic processes…
28 Aug 2026 NCT07430540